Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.58 |
| ▸ | GAK | O14976 | 3/20 | 0.58 |
| ▸ | FBP1 | P09467 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | BUB1 | O43683 | 2/20 | 0.54 |
| ▸ | STK10 | O94804 | 2/20 | 0.54 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.54 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.54 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.54 |
| ▸ | CARS1 | P49589 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614991 | 1.00 | EGFR (0.58) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL28814010 | 0.88 | EGFR (0.58) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL27369686 | 0.88 | EGFR (0.72) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL20127275 | 0.88 | EGFR (0.72) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507670 | 0.87 | EGFR (0.71) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL28407487 | 0.85 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29484155 | 0.85 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1507680 | 0.85 | EGFR (0.76) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29615047 | 0.85 | EGFR (0.76) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL26321 | 0.84 | EGFR (0.64) | EGFRFBP1ERBB2DAPK3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121434-A | Preparation method of high-purity quinazoline drug intermediate | 精华制药集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113264888-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-113121434-A | Preparation method of high-purity quinazoline drug intermediate | 精华制药集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-113121434-A | Preparation method of high-purity quinazoline drug intermediate | 精华制药集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| EP-2766356-B1 | QUINAZOLINE DERIVATIVES AS KINASES INHIBITORS AND METHODS OF USE THEREOF | TELIGENE LTD (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| WO-2013053206-A1 | QUINAZOLINE DERIVATIVES AS KINASES INHIBITORS AND METHODS OF USE THEREOF | TELIGENE LTD (CN) | 2013-04-18 | — | — | WO | disclosed |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ZHANG QIANG (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ZHANG QIANG (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011084796-A2 | NOVEL QUINAZOLINE DERIVATIVES | ZHANG QIANG | 2011-07-14 | — | — | WO | disclosed |
| EP-2318378-A2 | QUINAZOLINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2011-05-11 | — | — | EP | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885GAK 493/4885FBP1 3168/4885 |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, EGFR | EGFR 3/4885GAK 1632/4885FBP1 2501/4885 |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ERBB2, ERBB3, EGFR | EGFR 3/4885GAK 264/4885FBP1 645/4885 |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | WEE1, WEE2, EGFR | EGFR 3/4885GAK 1632/4885FBP1 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.